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Abstract
Background The preparation, administration and moni-
toring of intravenous (IV) applications are time consuming
and require human resources. We estimated the potential
time and cost savings by replacing antibiotics given 3–4
times daily with antibiotics with similar spectrum and
efficacy given once daily.
Methods The savings of indirect costs were estimated
based on the antibiotic consumption data of a two-year
period (i.e. 2007 and 2008), a nurse’s mean workload per
application and the average nurse’s salary in Switzerland.
Results The consumption of IV antibiotics in 2007 and
2008 at the University Hospital of Basel was 29.0 and
32.2 defined daily doses (DDD) per 100 patient days,
respectively. Nurses spent an estimated 13,786 h on the
application of the estimated 82,715 does of IV antibiotics. A
total of 56,404 applications or nursing staff time costs
of 338,436 Swiss Francs (CHF; 236,669 €), equal to 16% of
the overall costs spent on purchasing antibiotics in the year
2008, may have been saved by switching multiple-dose
antibiotics to a hypothetical once-daily antibiotic. Including
disposable materials, 21% or 456,884 CHF (319,499 €)
could be saved annually (purchase costs not taken into
account).
Conclusion We found a potential cost saving of 21% of
the purchase costs in a 750-bed institution. Hence, indirect
costs should be included in the calculation of the total cost
for the application of broad-spectrum IV antibiotics.
Switching from a 3–4 times daily application to a once-
daily antibiotic should be considered if a once-daily anti-
biotic is deemed equally effective and has a similar
spectrum.
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Introduction
The preparation, administration and monitoring of intra-
venous (IV) applications is time and cost consuming. In
pharmacoeconomic evaluations, it is important to include
the nursing staff time and the indirect costs associated with
the application of IV antibiotics to the direct costs for the
purchase of these antibiotics [1–3]. Detailed data on how
much nursing staff time and expenses may be saved by the
reduction of the number of IV applications of antibiotics in
a hospital is scarce and is limited to particular patient
groups [4, 5].
This analysis aims to calculate the amount of time and
the associated costs which can be saved from the per-
spective of a hospital by the use of an equally effective
hypothetic antibiotic which is applied once daily, replacing
the beta-lactam antibiotics which commonly require sev-
eral administrations per day.
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Methods
The University Hospital of Basel is a 750-bed tertiary care
centre serving about 27,000 admissions annually. The
consumption data of antibiotics in defined daily doses
(DDD) of the following IV antibiotics of interest were used
for this study (the typical number of applications per day at
our institution within parentheses): amoxicillin (4), amox-
icillin/clavulanate (3), penicillin (4), flucloxacillin (4),
piperacillin/tazobactam (3), cefepime (3), imipenem/cila-
statin (4) and meropenem (3). Because the definition of the
DDD does not necessarily represent the daily dose typi-
cally administered in our hospital, the number of grammes
per year was calculated as the basis for this analysis. The
data was extracted from the hospital pharmacy.
Analysis
On average, one application of an IV antibiotic takes
10 min, based on the validated computerised nursing
software that continuously measures nurses’ workload,
called ‘Leistungserfassung in der Pflege’ (LEP; http://
www.lep.ch/index.php/en/). LEP is the standard software
in most Swiss hospitals used to allocate nursing staff time.
Every single task conducted by nurses is registered by each
individual nurse either during breaks from clinical work or
at the end of the shift. According to the LEP system, an
application of IV antibiotics is a ‘simple’ intravenous
application and represents 10 min of work. The alterna-
tive categories in LEP, ‘very simple’, ‘complex’ and
‘very complex’ intravenous application (5, 20 and 30 min,
respectively), are only rarely used in the context of the
administration of IV antibiotics. Because the workload
cannot be registered in 1-min steps, a published average
duration of 6.77 min [4] for the duration of one IV appli-
cation instead of 10 min was assumed for sensitivity
analysis.
Based on the assumption that the total number of
applications per antibiotic would be replaced by a once-
daily IV application, the reduction in workload and costs
for IV applications per year were calculated. The costs are
reported in the local currency (Swiss Francs, CHF) and in
Euros (€), calculated at an exchange rate of 1.43.
Results
The overall consumption of antibiotics in 2007 and 2008
was 50.4 and 54.0 DDD per 100 patient days and the costs
were 2,441,465 CHF (1,707,318 €) and 2,155,607 CHF
(1,507,417 €), respectively. The consumption of IV anti-
biotics was 29.0 and 32.2 DDD per 100 patient days or
208,180 and 194,747 g of antibiotics per year, respectively
(Table 1). Therefore, about 59% of antibiotics were
administered intravenously.
A total of 56,404 applications may have been saved by
the use of a hypothetic once-daily antibiotic. As every
application takes, on average, 10 min and the usual hourly
wage of a nurse in Switzerland is 36 CHF (25 €), without
taking the purchase costs into account, a potential cost
saving of 338,436 CHF (236,669 €) per year was calcu-
lated. This cost saving equals 16% of the overall costs
Table 1 Consumption data of antibiotics of interest, potential reduction of applications per year, and time and cost savings
Antibiotic regimen Typical
no. of daily
applications
Grammes
per
application
Purchase
costs
per day
Grammes
used in 2007
Grammes
used in 2008
Mean no. of
applications
per year
Reduction in
the no. of
applications
Amoxicillin 4 2.0 58 CHF 3,403 3,330 1,683 1,262
Amoxicillin/clavulanate 1.2 g 3 1.2 9 CHF 22,205 20,570 17,823 11,882
Amoxicillin/clavulanate 2.2 g 3 2.2 14 CHF 30,706 34,472 14,813 9,875
Cefepime 3 2.0 74 CHF 2,194 8,625 2,705 1,803
Flucloxacillin 4 2.0 88 CHF 10,725 11,300 5,506 4,130
Imipenem/cilastatin 4 0.5 132 CHF 1,013 1,405 2,418 1,813
Meropenem 3 1.0 173 CHF 9,980 10,125 10,053 6,702
Penicillin 4 3.0 15 CHF 14,918 18,205 5,521 4,140
Piperacillin/tazobactam 3 4.5 78 CHF 99,604 100,148 22,195 14,796
Overall reduction of applications 56,404
Time savings in hours 9,401
Hourly wage of a nurse 36 CHF
Potential cost savings of wages 338,436 CHF
Purchase costs are based upon ex-factory prices in 2008 for the typical daily dose applied in our institution, i.e. the typical number of daily
applications multiplied by grammes per application; CHF Swiss Francs
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spent on purchasing antibiotics in the year 2008, i.e. the
direct costs.
The disposable materials, including 100 ml of sodium
chloride, would add another 2.10 CHF (1.47 €) per appli-
cation or 118,448 CHF (82,831 €) for the 56,404 applica-
tions potentially saved. In total, 456,884 CHF (319,499 €)
or 21% of the purchase costs could be saved without taking
the purchase costs into account.
Importantly, not only the cost savings due to a lower
number of administrations but also the potentially higher
purchase costs of the hypothetical antibiotic must be taken
into account. For example, the reduction of the number of
applications from three doses to one results in potential
cost savings of 12 CHF (8.40 €) per day and patient.
Assuming that, previously, piperacillin/tazobactam 4.5 g
(purchase costs of 78 CHF/55 € per day) was administered
thrice daily and replaced by the hypothetical antibiotic, the
once-daily administration of the latter would be less
expensive as long as its purchase cost would not exceed 90
CHF (63 €) per day. For comparison, the purchase costs for
ertapenem is 71 CHF (50 €) per day. In contrast, a once-
daily drug replacing amoxicillin/clavulanate (purchase
costs of 9 CHF/6.30 € per day) would need to cost less than
21 CHF (14.70 €) and, therefore, replacing amoxicillin/
clavulanate by either ertapenem or ceftriaxone (33 CHF/
23.10 €) does not result in an overall cost benefit.
Discussion
Our study shows in a tertiary-care hospital, that 21% of the
direct costs or 319,499 € per year could be saved by
reducing nursing staff time and the costs for disposable
materials if multiple-dose antibiotics are replaced by sin-
gle-dose antibiotics.
No such antibiotic to be applied once daily potentially
replacing beta-lactams in all indications exists nowadays.
There are some antibiotics (e.g. ceftriaxone and ertapenem)
approved for once-daily application which may replace
other beta-lactams used in this study in a majority of
indications. However, these antibiotics are approved only
for some specific infections and have different antimicro-
bial spectra. Therefore, the cost-saving potential would be
significantly smaller than what we have estimated in this
study. Furthermore, in order to reduce the spread of
resistance, antibiotics with a narrow spectrum should be
preferred and broad-spectrum antibiotics such as ertape-
nem should only be used if narrower antibiotics are not
more appropriate. Furthermore, due to the longer half-life
of antibiotics applied once daily, the duration of subopti-
mal concentrations of the antibiotic may be prolonged.
Therefore, from a theoretical point of view, the longer half-
life might be a disadvantage in regards to the selection and
development of resistance. However, such an emergence of
resistance was not frequently observed with once-daily IV
antibiotics. Continuous perfusion does not have this theo-
retical potential and could also reduce the workload for
nurses.
The reduction of the workload for health care workers
could either result in cost savings if the number of health
care workers would be reduced or, alternatively, the cost
saving can be referred to as opportunity costs and the time
saving could be used for other tasks, with the aim to
improve the quality of care. Once instead of three or four
times daily administration has potential benefits in addition
to save nursing staff time, such as, most importantly, ear-
lier discharge, which may further significantly reduce the
costs for the health care system [6, 7] and a reduction of
errors and omitted doses. In fact, recent studies found that
22–31% of doses were inappropriately prepared and
19–49% of doses were inappropriately administered [8, 9].
It is conceivable that these mistakes may be reduced by the
use of a once-daily regimen [7]. Furthermore, fewer
manipulations on the IV line may reduce the incidence of
secondary infections [10]. Importantly, early switching
from IV to the oral application of antibiotics is an even
better way to reduce the number of IV administrations [3]
and should not be neglected due to the potential ease and
cost savings of once-daily IV administrations.
Our results are based on a projection using assumptions.
This limits the interpretation and generalisability of our
results beyond our institution. We assumed that all anti-
biotics were given at the standard dose in terms of
grammes per application and the numbers of daily appli-
cations. The duration of the preparation and administration
of IV drugs can vary from drug to drug [1]. The 10 min of
nursing staff time required for applications of an antibiotic
assumed in this study is high in comparison to other studies
measuring the time for preparation and application [1, 4].
The assumption that the application of IV antibiotics takes
6.77 min as suggested in the analysis by Tice et al. [4]
would lower the potential of cost savings to 67.7% of the
findings of our primary analysis. However, in our hospital,
the preparation of antibiotics is done by nurses and not by
pharmacy technicians as, e.g. in the US, and the nursing
time of 10 min includes monitoring of the patient after
having started the infusion and stopping and removal of the
infusion at the end as well. Our study represents the nursing
time and costs in a Swiss hospital and both variables may
vary in other hospitals and other countries. However, the
importance of indirect costs and the potential to save
nursing time and costs by using a once-daily antibiotic
almost certainly applies all over the world. The wages—
although very conservatively estimated in this study—may
be significantly higher than in other countries. On the other
hand, our institution has a low consumption of antibiotics,
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therefore, potentially underestimating the additional
expenses for multiple doses in other institutions. The
additional costs for pharmacy technicians, depreciation of
medical equipment (e.g. infusion pumps), unallocated time
and overheads were not included in this cost analysis.
These additional costs are very difficult to evaluate and are
low compared to the costs of the nursing time calculated in
this study.
In conclusion, the dosing regimen strongly influences
the total cost for IV therapy: indirect costs for application
of the antibiotic should be included in the calculation of the
total cost for IV antibiotics. Switching from a 3–4 times
daily application to a once-daily antibiotic should be con-
sidered if a once-daily antibiotic with similar spectrum and
efficacy is available: the calculation of the situation at our
institution resulted in a potential cost saving for nursing
staff time of 16%, and 21% when including disposable
materials of the purchase costs in our institution.
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